The Food and Drug Administration (FDA) and Drug Enforcement Agency (DEA) have sent joint warning letters today to two online drug sellers. The letters concern the sale of Schedule II stimulants, including the amphetamine drug products marketed as Adderall, without the requirement of a valid prescription. The warning letters were issued to Kubapharm.com and Premiumlightssupplier.com.
Adderall is an FDA-approved prescription drug used for the purposes of treating attention deficit disorder. However the medication has a high potential for abuse and addiction and is only licensed for use under the supervision of a licensed health care professional. The FDA and DEA also note that: “Consumers who buy prescription drugs from unsafe online pharmacies may put their health at risk because the products, while being marketed as authentic, may be counterfeit, contaminated, expired or otherwise harmful.” The letter specifically recommends that any consumer who has purchased from these sites dispose of the medication and not purchase further medication without a prescription.
The letter notes that the operators have 15 business days to respond regarding specific steps that have been or will be taken to address the violations and prevent future sales without prescriptions. The letters also note the steps that must be taken to be in compliance, including no further sales of misbranded medications under the Ryan Height Online Pharmacy Act and registration with the DEA to specifically distribute controlled substances.